Irritable Bowel Syndrome – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Irritable Bowel Syndrome – Pipeline Review, H2 2020’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome

– The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

Allergan Ltd

Ardelyx Inc

AsiaBiome

Assembly Biosciences Inc

Axim Biotechnologies Inc

Bausch Health Companies Inc

Biomica

Boston Pharmaceuticals Inc

CB2 Therapeutics Inc

CinRx Pharma LLC

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Exeliom Biosciences SAS

GEXVal Inc

IGY Immune Technologies & Life Sciences Inc

ImmuneBiotech AB

Immunic Inc

Ironwood Pharmaceuticals Inc

ISOThrive Inc

Jiangsu Aosaikang Pharmaceutical Co Ltd

Merck & Co Inc

Metacrine Inc

MGC Pharmaceuticals Ltd

Napo Pharmaceuticals Inc

Novome Biotechnologies Inc

Oncocross Co Ltd

Orphomed Inc

Oxford Cannabinoid Technologies Ltd

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

Renexxion LLC

Seed Health Inc

Sentia Medical Sciences Inc

Serentrix LLC

Servatus Ltd

Synthetic Biologics Inc

Velicept Therapeutics Inc

Virios Therapeutics LLC

Vitality Biopharma Inc

Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Irritable Bowel Syndrome- Overview

Irritable Bowel Syndrome- Therapeutics Development

Irritable Bowel Syndrome- Therapeutics Assessment

Irritable Bowel Syndrome- Companies Involved in Therapeutics Development

Irritable Bowel Syndrome- Drug Profiles

Irritable Bowel Syndrome- Dormant Projects

Irritable Bowel Syndrome- Discontinued Products

Irritable Bowel Syndrome- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Irritable Bowel Syndrome – Pipeline by 4D Pharma Plc, H2 2020

Irritable Bowel Syndrome – Pipeline by Allergan Ltd, H2 2020

Irritable Bowel Syndrome – Pipeline by Ardelyx Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by AsiaBiome, H2 2020

Irritable Bowel Syndrome – Pipeline by Assembly Biosciences Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by Axim Biotechnologies Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by Bausch Health Companies Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by Biomica, H2 2020

Irritable Bowel Syndrome – Pipeline by Boston Pharmaceuticals Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by CB2 Therapeutics Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by CinRx Pharma LLC, H2 2020

Irritable Bowel Syndrome – Pipeline by ConSynance Therapeutics Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by Cosmo Pharmaceuticals NV, H2 2020

Irritable Bowel Syndrome – Pipeline by Dong-A ST Co Ltd, H2 2020

Irritable Bowel Syndrome – Pipeline by Eisai Co Ltd, H2 2020

Irritable Bowel Syndrome – Pipeline by Exeliom Biosciences SAS, H2 2020

Irritable Bowel Syndrome – Pipeline by GEXVal Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by IGY Immune Technologies & Life Sciences Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by ImmuneBiotech AB, H2 2020

Irritable Bowel Syndrome – Pipeline by Immunic Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by Ironwood Pharmaceuticals Inc, H2 2020

Irritable Bowel Syndrome – Pipeline by ISOThrive Inc, H2 2020

rritable Bowel Syndrome – Dormant Projects, H2 2020

Irritable Bowel Syndrome – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports